Sodium Valproate: A Comprehensive Guide

Sodium valproate is a widely prescribed antiepileptic medication that plays a crucial role in managing various neurological and psychiatric disorders. First introduced in the 1960s, sodium valproate has become a cornerstone in the treatment of epilepsy and bipolar affective disorder. It is derived from valproic acid and works by stabilising electrical signals in the brain, thus preventing seizures and mood swings. Available under brand names such as Epilim and Depakote, sodium valproate is recognised by the World Health Organization as an essential medicine due to its broad efficacy and safety when used appropriately.

Image source Google

Phenytoin: An In-Depth Analysis

Phenytoin, a hydantoin derivative, is one of the most extensively utilised antiepileptic drugs (AEDs). It was first synthesised in 1908 and has been in clinical use since the 1930s. Despite the advent of newer-generation anticonvulsants, phenytoin remains a cornerstone in the management of seizure disorders due to its efficacy, cost-effectiveness, and broad therapeutic index. By modulating voltage-gated sodium channels, phenytoin stabilises neuronal membranes and attenuates excessive excitatory activity, making it a vital agent in controlling epileptic seizures and related neurological conditions.

Image source Google

Levetiracetam

Levetiracetam (LEV) is a second-generation antiepileptic drug (AED) with a unique pharmacological profile, favorable safety margin, and minimal drug interaction potential. Unlike traditional AEDs, LEV exerts its antiepileptic effects primarily via synaptic vesicle protein 2A (SV2A) modulation, distinguishing it from sodium channel blockers and gamma-aminobutyric acid (GABA) modulators. Its negligible hepatic metabolism and renal excretion make it an optimal choice for patients with hepatic impairment and those on polypharmacy regimens. This review examines the clinical applications, pharmacokinetics, comparative efficacy, and recent advancements in LEV research.

Pages